Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
Foundations invest DKK 280 million in biomedical company
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
NMD Pharma cleared for spinal muscular atrophy trial
Management team — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma Raises €35 Million in a new Financing — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma Raises €35M Financing - FinSMEs
NMD Pharma receives Orphan Drug Designation from FDA for NMD670 for the Treatment of Myasthenia Gravis | BioSpace
Thomas Holm Pedersen - Roller i dansk erhvervsliv
Stor pariserfond investerer i dansk biotekselskab: Scorer over 250 mio. kr. for anden gang
Other news — News — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud" — MedWatch
We will be taking part in the ICFSR conference — NMD Pharma
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
NMD Pharma - PIR International
